News / Taiwan / cnyes
Lumosa Therapeutics August Revenue Skyrockets Over 5000% YoY
Health Technology · Biotechnology · cnyes · 2026-09-08
6535
Lumosa Therapeutics (6535) reported a massive 5,135.84% year-over-year revenue surge in August, with the stock outperforming the biotech sector index.
What Happened
Revenue Surge: Lumosa Therapeutics (6535) reported August 2026 revenue of NT$9.06 million, representing an extraordinary 5,135.84% year-over-year increase. The month-over-month growth was even more dramatic at 11,512.82%, indicating a significant shift in monthly revenue.
Year-to-Date Results: For the first eight months of 2026, cumulative revenue totaled NT$18.75 million, a modest 1.27% increase year-to-date. Despite the massive monthly spike, the cumulative growth remains relatively stable.
Stock and Market Data: The stock is trading at NT$77.8, up 4.01% over the past five days, outperforming the biotech industry index's 1.03% gain. Institutional investors have been net sellers, with foreign investors selling 225 shares.
Industry Context: Lumosa Therapeutics operates in the biotechnology sector. Investors should be aware of the high volatility associated with biotech stocks; these figures are for informational purposes only.
Read original
More in Health Technology
Health Technology · cnyes · 2026-09-08
Xufu (4119) reported August 2026 revenue of NT$149 million, a 187.52% year-over-year surge, with year-to-date revenue growth at 14.21%.
4119
Health Technology · cnbc · 2026-09-08
AstraZeneca's experimental COPD drug, tozorakimab, showed significant efficacy in late-stage trials, bolstering the company's multi-billion dollar sales outlook.
AZN, AZN, SNY, GSK, GILD, SNY, REGN, GSK, IBB
Health Technology · economic_daily · 2026-09-08
Taiwanese biotech companies Fortune and PharmaEssentia posted record-breaking August revenues, driven by strong product sales and international market expansion.
Latest in Taiwan
Finance · cnyes · 2026-09-08
Chang Hwa Bank announced an 8-month net profit of NT$15.57 billion, driven by strong lending and wealth management performance, resulting in an EPS of NT$1.29.
2801
Process Industries · economic_daily · 2026-09-08
Fuchang-KY reported August revenue of NT$1.192 billion, marking a 42.4% year-on-year increase, driven by strong seasonal demand and holiday restocking.
8411
Technology Services · cnyes · 2026-09-08
Taiwan Mobile CEO Jamie Lin says a successful acquisition of SYSTEX could propel the company's revenue to challenge the industry leader by next year.
2412, 3045, 6214
Producer Manufacturing · economic_daily · 2026-09-08
Junxing-KY reported record cumulative revenue of NT$2.125 billion for the first eight months, bolstered by strong demand for robotics and smart transmission.
4571